Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stibophen
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Stibophen is an anthelmintic drug classified as a trivalent antimony compound and used primarily for the treatment of schistosomiasis (a disease caused by parasitic flatworms) via intramuscular injection. It was originally developed by Bayer. The drug acts by inhibiting the enzyme phosphofructokinase in *Schistosoma* species, which is essential for glycolysis. This inhibition occurs at least partly through binding to the sulfhydryl (–SH) group of the enzyme. As a result, glycolysis in the parasite is blocked, leading to paralysis; affected worms lose their grip on mesenteric veins and are subsequently cleared from circulation and phagocytosed by liver cells[1][2][3][5].
- Brand names
- FouadinFuadin
- Other names
- stibophenumcorystibinneoantimosanstibophen heptahydrate
02
Targets
PFK (Phosphofructokinase-1 liver type)
Beyond the preview
Go deeper on stibophen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stibophen.